≡ Risteys
R8

Documentation Changelog GitHub Contact & Feedback

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

PheWeb

SGLT2INH

No definition available.

Endpoint definition

↥
FinnGen phenotype data

356077 individuals

diagram downward connector

Apply sex-specific rule None

356077

diagram downward connector

Check conditions None

356077

diagram downward connector
diagram bullet

Filter registries

Medicine purchases: ATC A10BJ

3773

diagram downward connector

Check pre-conditions, main-only, mode, ICD version None

3392

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

3392

diagram downward connector

Include endpoints None

3392

diagram downward connector
SGLT2INH

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 3392 1699 1693
Unadjusted prevalence (%) 0.95 0.86 1.08
Mean age at first event (years) 61.12 60.17 62.08

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.08 4.69 [3.08, 7.13] 4.9e-13 84
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: SGLT2INH – Sodium-glucose co-transporter 2 (SGLT2) inhibitors
GWS hits:

Survival analyses between endpoints

↥

Plot

before Sodium-glucose co-transporter 2 (SGLT2) inhibitors
after Sodium-glucose co-transporter 2 (SGLT2) inhibitors

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Sodium-glucose co-transporter 2 (SGLT2) inhibitors

↥